908 Devices Inc. - Common Stock (MASS)

NIRLab scan volume climbed 74% as the installed base passed 4,400 devices.

908 Devices (NASDAQ:MASS) reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally. The company now expects full-year revenue of $68.5 million to $70 million, repres

908 Devices (NASDAQ:MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said

Revenue grew 23% to $16.1 million as adjusted EBITDA loss improved 50%.

908 Devices (NASDAQ:MASS) is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion. Chief Executive Officer

908 Devices (NASDAQ:MASS) reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing

908 Devices MASS Q1 2026 Earnings Transcript

908 Devices (MASS) Q4 2025 Earnings Transcript

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

908 Devices (MASS) Q3 2025 Earnings Transcript

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.